Anti-CD19 CAR-T cells have shown unprecedented clinical effects in treating various diseases, including acute lymphoblastic leukemia (ALL) in children and adults, non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL) (4–8). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.